CyPath Lung Detects Stage 1A Lung Cancer in High-Risk Patient with Inconclusive Imaging.

bioAffinity Technologies' CyPath Lung test detected stage 1A lung cancer in a high-risk patient with inconclusive imaging and low-risk serum test results. The noninvasive sputum test caught the rare cancer in time for curative surgery. The case study highlights the importance of CyPath Lung in providing diagnostic clarity and early intervention for high-risk patients.

bioAffinity Technologies, Inc. (BIAF; BIAFW), a biotechnology company specializing in noninvasive diagnostics and early cancer detection, recently shared a compelling case study demonstrating the effectiveness of its flagship test, CyPath® Lung. The test detected Stage 1A lung cancer in a high-risk patient whose previous diagnostic tests and imaging results suggested a low probability of malignancy [1].

The patient, a 62-year-old woman with a history of heavy smoking and COPD, initially presented in 2022 with a suspicious left upper lobe ground-glass opacity (GGO) on a CT scan. Subsequent tests, including a PET scan and a blood-based risk test, indicated a low probability of cancer. Despite these inconclusive results, the patient's condition progressed, and a July 2024 scan revealed a transition to a more solid nodule, raising clinical concern.

When the patient opted against further surveillance CT scans and a follow-up PET scan, her physician ordered the CyPath® Lung test in March 2025. The test result, classified as "likely malignancy," prompted the care team to recommend surgical consultation. The patient underwent a wedge resection of the upper left lung in June 2025, and final pathology confirmed Stage 1A invasive mucinous adenocarcinoma.

CyPath® Lung uses advanced flow cytometry and artificial intelligence to identify cell populations in patient sputum that indicate malignancy. Clinical study results have shown that CyPath® Lung has 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with small lung nodules less than 20 millimeters [1].

The case study underscores the importance of CyPath Lung in providing diagnostic clarity and enabling early intervention for high-risk patients. The ability to detect lung cancer at an early stage when traditional diagnostic tests indicated a low probability of malignancy can significantly improve patient outcomes and increase survival rates.

References:
[1] https://www.stocktitan.net/news/BIAF/case-study-cy-path-lung-detects-stage-1a-lung-cancer-in-high-risk-jp2e8eur8t1w.html
[2] https://finance.yahoo.com/news/case-study-cypath-lung-detects-120000405.html